Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Savara Inc. (SVRA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases, and its filings offer detailed insight into the development and financing of its lead program, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Through this page, readers can review current and historical reports such as Forms 8-K, which describe material events including public offerings of common stock and pre-funded warrants, royalty funding agreements tied to potential future U.S. net sales of MOLBREEVI, and updates to corporate presentations. Filings also confirm that Savara’s common stock trades on The Nasdaq Global Select Market under the symbol SVRA and describe the company’s status as a clinical stage biopharmaceutical company focused on rare respiratory diseases.
Key documents for investors include periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain information on research and development expenses, general and administrative costs, and other financial data related to the MOLBREEVI program and corporate operations. Current reports on Form 8-K highlight transactions such as underwritten public offerings, the entry into material definitive agreements, and royalty funding arrangements.
Stock Titan enhances these filings with AI-powered summaries that help explain the significance of complex disclosures, including capital-raising transactions, royalty structures, and covenants described in agreements. Users can quickly understand how specific filings relate to Savara’s rare respiratory disease focus, its Phase 3 development of MOLBREEVI, and its preparation for potential commercialization, while still having direct access to the full text of each SEC document.
Savara Inc. is asking stockholders to approve several items at its 2026 virtual annual meeting while advancing its lead drug candidate MOLBREEVI for autoimmune pulmonary alveolar proteinosis. Regulatory reviews are underway in the U.S., EU, and UK, including an FDA Priority Review with an action date of November 22, 2026.
The company highlights recent financing actions: a $149.5 million equity raise, a $75 million royalty funding agreement with RTW, and an amended debt facility allowing up to $75 million of additional funding upon FDA approval. Proposals include electing six directors, doubling authorized common shares from 300,000,000 to 600,000, increasing the 2024 Omnibus Incentive Plan share pool by 18,900,000, ratifying RSM US LLP as auditor, and holding an advisory vote on executive pay.
Savara Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 4, 2026, asking stockholders to elect six directors and vote on corporate governance and compensation proposals.
The company highlights regulatory milestones for its investigational therapy MOLBREEVI: an FDA Priority Review action date of August 22, 2026, an EU decision expected in Q1 2027, and a UK decision expected in Q4 2026. Savara reports it completed a $149.5 million equity financing, entered a $75 million royalty funding agreement, and amended a debt facility to permit up to $75 million additional debt funding upon FDA approval.
Key votes include approval to increase authorized common shares from 300,000,000 to 600,000,000, an 18,900,000-share increase to the 2024 Omnibus Incentive Plan, ratification of RSM US LLP as auditor, and an advisory vote on executive compensation. Shares outstanding were 204,922,140 as of April 6, 2026.
Savara Inc Chief Financial Officer David L. Lowrance exercised several stock option grants on March 18, 2026, acquiring a total of 366,747 shares of Common Stock through option exercises at strike prices ranging from $1.11 to $4.45 per share. To cover exercise costs and tax obligations, 116,760 shares of Common Stock were withheld by the issuer in transactions coded as F, which are tax-withholding dispositions rather than open‑market sales. Following these transactions, Lowrance directly owned 536,032 shares of Savara common stock. The derivative transactions reflect routine option exercises tied to grants that vest in quarterly installments, as described in the footnotes.
Savara Inc. entered into a new headquarters lease with ML7 Yardley Partners, LP for approximately 10,795 square feet of office space at 19 W. College Avenue, Suite 200, Yardley, Pennsylvania. The lease term begins on July 1, 2026 and runs through December 1, 2031, with an option to extend for an additional five years.
Savara will pay monthly base rent of about $28,337 in the first year, with annual increases of roughly 2%. Aggregate base rent over the term is approximately $1,780,900, reflecting five months of rent abatement. The company will also pay its share of operating expenses, taxes, and utilities and has provided a $28,337 security deposit.
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, built around its sole product candidate, MOLBREEVI (molgramostim inhalation solution) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The drug is an inhaled form of GM-CSF delivered via PARI’s proprietary eFlow nebulizer.
The company’s Phase 3 IMPALA-2 trial in autoimmune PAP met its primary endpoint, showing statistically significant improvement in gas exchange (DLCO) and supporting clinical benefit on respiratory quality of life and exercise capacity, with generally well-tolerated safety. A pediatric trial (IMPACT) and an expanded access program are ongoing.
Savara resubmitted a biologics license application for MOLBREEVI in autoimmune PAP in December 2025, and in February 2026 the FDA filed the application and granted Priority Review. The candidate holds multiple regulatory incentives, including Orphan Drug, Fast Track, Breakthrough Therapy, Innovation Passport, and Promising Innovative Medicine designations, as well as European patents protecting the liquid formulation and the MOLBREEVI–eFlow drug-device combination into the 2040s.
The company outsources manufacturing to GEMA, Fujifilm, and Patheon and has exclusive device supply from PARI. Under a purchase and sale agreement with funds managed by RTW Investments, Savara may receive $75 million upon FDA approval of MOLBREEVI by March 31, 2027, in exchange for tiered royalties on U.S. net sales up to an aggregate $187.5 million, with a buy-back option tied to certain change-of-control events.
Venrock-affiliated investment entities report beneficial ownership of 20,881,288 Savara Inc. shares, representing 9.99% of the common stock as of December 31, 2025. This stake comes from common shares and pre-funded warrants held across several Venrock Healthcare Capital Partners funds.
The pre-funded warrants include a 9.99% Beneficial Ownership Blocker, which prevents additional exercises that would push the group’s ownership above that level. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Savara.
Savara Inc director Joseph S. McCracken exercised stock options on February 16, 2026 to acquire 1,807 shares of common stock at $1.76 per share. These options, granted at an exercise price of $1.76, had vested in twelve equal quarterly installments beginning on March 15, 2017. After this option exercise, McCracken directly holds 302,644 shares of Savara common stock.
Savara Inc. received an updated ownership report from TCG Crossover entities and Chen Yu. They report beneficial ownership of 12,362,205 shares of Savara common stock, representing 6.1% of the class, based on 203,467,845 shares outstanding as of November 12, 2025.
The shares are held of record by TCG Crossover Fund I, L.P., with TCG Crossover GP I, LLC as its general partner and Chen Yu as sole managing member, giving them shared voting and dispositive power. The filers state the holdings are not for the purpose of changing or influencing control of Savara.
Savara Inc. (SVRA) received an amended Schedule 13G filing from a group of Frazier Life Sciences investment entities reporting beneficial ownership of less than 5% of its common stock.
Frazier Life Sciences Public Fund, L.P. directly holds 8,343,048 shares, representing 4.1% of the class based on 203,467,845 shares outstanding as of November 12, 2025. Frazier Life Sciences X, L.P. directly holds 279,365 shares (0.1%), and Frazier Life Sciences XI, L.P. directly holds 1,239,888 shares (0.6%).
The reporting persons certify the securities were not acquired or held to change or influence control of Savara and disclaim being part of a control group, other than for limited nomination activities cited in the certification language.